SEC Form 4 · accession 0001209191-18-020867
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Matthew Stark
Officer — Exec. VP Chief Legal Officer
Period of report
Mar 17, 2018
Accepted (ET)
Mar 20, 2018 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Mar 17, 2018 | M | 2,358 | — | A | 5,332 | D | |
| Ordinary SharesF1 | Mar 19, 2018 | S | 2,358 | $18.38 | D | 2,974 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F4,F1 | — | Mar 17, 2018 | M | 2,358 | D | — | — | Ordinary Shares | 2,358 | 4,717 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F4Restricted share units were granted on March 17, 2016, with 2,358 vesting on each of March 17, 2018 and March 17, 2019 and 2,359 vesting on March 17, 2020.